A Cutting-Edge Cancer Treatment Is Under FDA Investigation—for Cancer Risk
Science, Spoken - Un pódcast de WIRED
CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers. Read this story here.
